Capricor Therapeutics, Inc. expected to post a loss of 59 cents a share - Earnings Preview
Capricor Therapeutics, Inc. <CAPR.OQ> expected to post a loss of 59 cents a share - Earnings Preview
Capricor Therapeutics, Inc. CAPR.OQ CAPR.O is expected to show no change in quarterly revenue when it reports results on August 13 for the period ending June 30 2026
LSEG's mean analyst estimate for Capricor Therapeutics, Inc. is for a loss of 59 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 10 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Capricor Therapeutics, Inc. is $5.00, about 29.9% above its last closing price of $3.85
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.52 | -0.53 | -0.59 | Missed | -11 |
Dec. 31 2026 | -0.51 | -0.54 | -0.62 | Missed | -14.8 |
Sep. 30 2025 | -0.56 | -0.55 | -0.54 | Beat | 1.4 |
Jun. 30 2025 | -0.48 | -0.47 | -0.57 | Missed | -21.6 |
Mar. 31 2025 | -0.31 | -0.32 | -0.53 | Missed | -67.4 |
Dec. 31 2024 | -0.32 | -0.26 | -0.16 | Beat | 39.2 |
Sep. 30 2024 | -0.35 | -0.36 | -0.38 | Missed | -6 |
Jun. 30 2024 | -0.35 | -0.36 | -0.35 | Beat | 1.7 |
This summary was machine generated August 11 at 20:41 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)